Cosmetic cross-reference

Cyanocobalamin

CAS 68-19-9

Cyanocobalamin (CAS 68-19-9) is a pharmaceutical compound with 7 bioactivity targets and 12,148 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

12,148

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE DrugCentral 055904D152D6

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Cyanocobalamin

CAS Number

68-19-9

UNII

P6YC3EG204

InChIKey

FDJOLVPMNUYSCM-UVKKECPRSA-L

ChEMBL ID

CHEMBL2110563

DrugCentral Struct ID

4196

Source Match

DrugCentral (CAS), FDA GSRS (UNII)

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 7 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
Methionine synthase Enzyme	-	-	-	Homo sapiens
Methionine synthase reductase Enzyme	-	-	-	Homo sapiens
Protein amnionless Unclassified	-	-	-	Homo sapiens
Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial Enzyme	-	-	-	Homo sapiens
Methylmalonic aciduria type A protein, mitochondrial Enzyme	-	-	-	Homo sapiens
Transcobalamin-2 Secreted	-	-	-	Homo sapiens
Transcobalamin-1 Secreted	-	-	-	Homo sapiens

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Pemphigus	5402	1921.221	10034280
Systemic lupus erythematosus	5769	1848.087	10042945
Toxicity to various agents	1196	1754.487	10070863
Completed suicide	197	1667.557	10010144
Glossodynia	4998	1620.09	10018388
Hand deformity	4337	1328.23	10061194
Alopecia	7286	1299.079	10001760
Rheumatoid arthritis	6224	1280.903	10039073
Abdominal discomfort	7463	1269.924	10000059
Arthropathy	5774	1266.457	10003285
Drug abuse	149	1137.977	10013654
Drug interaction	1752	1113.121	10013710
Wound	4257	1084.675	10052428
Maternal exposure during pregnancy	4817	1000.375	10071408
Pain	13874	923.716	10033371
Synovitis	4317	880.763	10042868
Joint swelling	6825	848.546	10023232
Discomfort	3989	815.15	10013082
Swelling	5816	814.138	10042674
Anti-cyclic citrullinated peptide antibody positive	2941	803.469	10068798
Arthralgia	11156	770.336	10003239
Infusion related reaction	5708	744.972	10051792
Contraindicated product administered	4824	744.668	10078504
Pericarditis	3269	741.858	10034484
Death	4888	653.98	10011906
Intentional overdose	187	651.21	10022523
Acute kidney injury	3263	596.667	10069339
Overdose	812	562.465	10033295
Febrile neutropenia	1108	552.155	10016288
Fatigue	16311	527.159	10016256
Psoriatic arthropathy	2354	502.534	10037162
Duodenal ulcer perforation	2095	492.315	10013849
Rheumatoid factor positive	1994	489.73	10039080
Helicobacter infection	2175	475.217	10054263
Musculoskeletal stiffness	3998	474.328	10052904
Nasopharyngitis	5139	439.975	10028810
Suicide attempt	229	418.84	10042464
Hepatic enzyme increased	4054	408.504	10060795
Product use issue	4747	402.115	10076309
Exposure during pregnancy	3051	388.977	10073513
Cardiac arrest	780	382.206	10007515
Drug reaction with eosinophilia and systemic symptoms	120	335.182	10073508
Drug intolerance	5541	331.253	10061822
Disease progression	1277	329.193	10061818
Rhabdomyolysis	368	319.187	10039020
Depressed level of consciousness	328	319.089	10012373
Therapeutic product effect decreased	3698	315.706	10082201
Neutropenia	2109	311.026	10029354
Multiple organ dysfunction syndrome	531	304.644	10077361
Knee arthroplasty	1315	284.858	10023469

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE PharmGKB 2 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

MTHFR (PA245) rs1801131

Genotypes GG + GT are associated with increased overall survival when treated with bevacizumab, cyanocobalamin, folic acid and pemetrexed in people with Head and Neck Neoplasms as compared to genotype TT.

Evidence: -; PMID 21343546

MTHFR rs1801131

Neoplasms

Evidence: 3; PMID 4

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
cyanocobalamin	11248	SU	MTHSPL
CYANOCOBALAMIN	11248	SU	MTHSPL
Cyanocobalamin	11248	SU	MTHSPL

SOURCE SIDER 63 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Anaphylactic shock	cyanocobalamin	LLT	C0002792
Anaphylactic shock	cyanocobalamin	PT	C0002792
Anxiety	cyanocobalamin	LLT	C0003467
Anxiety	cyanocobalamin	PT	C0003467
Arthritis	cyanocobalamin	LLT	C0003864
Arthritis	cyanocobalamin	PT	C0003864
Asthenia	cyanocobalamin	LLT	C0004093
Asthenia	cyanocobalamin	PT	C0004093
Back pain	cyanocobalamin	LLT	C0004604
Back pain	cyanocobalamin	PT	C0004604
Cardiac failure congestive	cyanocobalamin	LLT	C0018802
Cardiac failure congestive	cyanocobalamin	PT	C0018802
Coordination abnormal	cyanocobalamin	LLT	C0520966
Coordination abnormal	cyanocobalamin	PT	C0520966
Dermatitis	cyanocobalamin	PT	C0011603
Diarrhoea	cyanocobalamin	LLT	C0011991
Diarrhoea	cyanocobalamin	PT	C0011991
Dizziness	cyanocobalamin	LLT	C0012833
Dizziness	cyanocobalamin	PT	C0012833
Dyspepsia	cyanocobalamin	LLT	C0013395
Dyspepsia	cyanocobalamin	PT	C0013395
Dyspnoea	cyanocobalamin	LLT	C0013404
Dyspnoea	cyanocobalamin	PT	C0013404
Gait disturbance	cyanocobalamin	LLT	C0575081
Gait disturbance	cyanocobalamin	PT	C0575081
Generalized aching	cyanocobalamin	LLT	C0281856
Glossitis	cyanocobalamin	LLT	C0017675
Glossitis	cyanocobalamin	PT	C0017675
Headache	cyanocobalamin	LLT	C0018681
Headache	cyanocobalamin	PT	C0018681
Hypoaesthesia	cyanocobalamin	LLT	C0020580
Hypoaesthesia	cyanocobalamin	PT	C0020580
Infection	cyanocobalamin	LLT	C0009450
Infection	cyanocobalamin	PT	C0009450
Musculoskeletal discomfort	cyanocobalamin	PT	C0948594
Myalgia	cyanocobalamin	LLT	C0231528
Myalgia	cyanocobalamin	PT	C0231528
Nausea	cyanocobalamin	LLT	C0027497
Nausea	cyanocobalamin	PT	C0027497
Nervousness	cyanocobalamin	LLT	C0027769
Nervousness	cyanocobalamin	PT	C0027769
Pain	cyanocobalamin	PT	C0030193
Paraesthesia	cyanocobalamin	LLT	C0030554
Paraesthesia	cyanocobalamin	PT	C0030554
Peripheral vascular disorder	cyanocobalamin	LLT	C0085096
Peripheral vascular disorder	cyanocobalamin	PT	C0085096
Polycythaemia vera	cyanocobalamin	LLT	C0032463
Polycythaemia vera	cyanocobalamin	PT	C0032463
Pruritus	cyanocobalamin	LLT	C0033774
Pruritus	cyanocobalamin	PT	C0033774
Pulmonary oedema	cyanocobalamin	LLT	C0034063
Pulmonary oedema	cyanocobalamin	PT	C0034063
Rash	cyanocobalamin	LLT	C0015230
Rash	cyanocobalamin	PT	C0015230
Rhinitis	cyanocobalamin	LLT	C0035455
Rhinitis	cyanocobalamin	PT	C0035455
Swelling	cyanocobalamin	LLT	C0038999
Swelling	cyanocobalamin	PT	C0038999
Tension	cyanocobalamin	PT	C0233494
Thrombosis	cyanocobalamin	LLT	C0040053
Thrombosis	cyanocobalamin	PT	C0040053
Vomiting	cyanocobalamin	LLT	C0042963
Vomiting	cyanocobalamin	PT	C0042963

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Cyanocobalamin used for in pharmaceutical contexts?

Cyanocobalamin (CAS 68-19-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Cyanocobalamin?

Cyanocobalamin has 12,148 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pemphigus, Systemic lupus erythematosus, Toxicity to various agents, Completed suicide, Glossodynia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Cyanocobalamin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for CYANOCOBALAMIN with EU status "permitted".

What clinical phase is Cyanocobalamin in?

No phase 1-4 clinical development badge is rendered for Cyanocobalamin because the matched compound identifier rows do not contain a max-phase value.

What bioactivity targets are documented for Cyanocobalamin?

Cyanocobalamin has 7 bioactivity rows in this page query. Rendered target entries include Methionine synthase, Methionine synthase reductase, Protein amnionless, Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial, Methylmalonic aciduria type A protein, mitochondrial.